Pharmacoeconomic review report : Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue pharma)

Pharmacoeconomic review report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue pharma)

Netupitant/palonosetron (Akynzeo) is an oral fixed-dose combination of netupitant, a neurokinin-1 (NK1) receptor antagonist (RA), and palonosetron, a 5-hydroxytryptamine-3 (5-HT3) RA, available as a 300 mg/0.5 mg oral capsule. In combination with dexamethasone, netupitant/palonosetron (NEPA) is indi...

Full description

Bibliographic Details
Main Author: Canadian Agency for Drugs and Technologies in Health (author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Format: eBook
Language:Inglés
Published: Ottawa (ON) : CADTH 2018.
Series:Common drug review clinical review report.
Subjects:
Antiemetics.
See on Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269006719

Similar Items

Similar Items